Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.38 |
| ▸ | KDM4A | O75164 | 4/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020960 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAKDM4C | |
| SCHEMBL614192 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAKDM4C | |
| SCHEMBL613011 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAKDM4C | |
| SCHEMBL611893 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAKDM4C | |
| SCHEMBL8411431 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAKDM4C | |
| SCHEMBL614348 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAKDM4C | |
| SCHEMBL23011936 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAKDM4C | |
| SCHEMBL11587394 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAKDM4C | |
| SCHEMBL613981 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAKDM4C | |
| SCHEMBL18807938 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421874-B1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2015-09-30 | — | — | EP | claimed |
| US-8979996-B2 | Composition containing quaternary amino-functional organosilicon compunds and production and use thereof | EVONIK DEGUSSA GMBH (DE) | 2015-03-17 | — | — | US | claimed |
| US-20140208981-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2014-07-31 | — | — | US | claimed |
| US-8728225-B2 | Composition containing quaternary amino-functional organosilicon compounds and production and use thereof | EVONIK DEGUSSA GMBH (DE) | 2014-05-20 | — | — | US | claimed |
| EP-2421874-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | Evonik Degussa GmbH (DE) | 2012-02-29 | — | — | EP | claimed |
| US-20120037040-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2012-02-16 | — | — | US | claimed |
| WO-2010121873-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2010-10-28 | — | — | WO | claimed |
| WO-2024112876-A2 | SPLIT SYNTHESIS OF LONG RNAS | PRIME MEDICINE, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4194563-A1 | TRANSPOSASE COMPETITOR CONTROL SYSTEM | Kapa Biosystems, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-102405224-B | Comprise composition and the Synthesis and applications thereof of season amino-functional silicoorganic compound | EVONIK DEGUSSA GMBH (DE) | 2015-12-16 | — | — | CN | disclosed |
| EP-2421874-B1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| CN-102405263-A | Dispersion containing silicon dioxide particles surface-modified with quaternized amino-functional organosilicon compounds | EVONIK DEGUSSA GMBH | 2012-04-04 | — | — | CN | disclosed |
| EP-2421874-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | Evonik Degussa GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| EP-2421921-A1 | DISPERSION CONTAINING SILICA PARTICLES SURFACE-MODIFIED WITH QUATERNARY, AMINOFUNCTIONAL ORGANOSILICON COMPOUNDS | Evonik Degussa GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20120037040-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120006228-A1 | DISPERSION CONTAINING SILICA PARTICLES SURFACE-MODIFIED WITH QUATERNARY, AMINOFUNCTIONAL ORGANOSILICON COMPOUNDS | EVONIK DEGUSSA GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| WO-2010121878-A1 | DISPERSION CONTAINING SILICA PARTICLES SURFACE-MODIFIED WITH QUATERNARY, AMINOFUNCTIONAL ORGANOSILICON COMPOUNDS | EVONIK DEGUSSA GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121873-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | ALDH1A1 3948/4885TSHR 788/4885DNM1 2580/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885TSHR 3319/4885DNM1 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.